论文部分内容阅读
国外临床试验已经证明血小板糖蛋白b/a受体拮抗剂能够降低急性冠脉综合症患者PCI术后近期终点事件(再次心肌缺血、急性心肌梗塞、猝死),也能够改善梗死相关血管TIMI血流,明显改善再灌注治疗的效果和预后[1]。本研究旨在回顾对比分析国产GP b/a受体拮抗剂欣维宁对急性心肌梗塞患
Foreign clinical trials have shown that platelet glycoprotein b / a receptor antagonists can reduce acute end-point events (myocardial ischemia, acute myocardial infarction, sudden death) in patients with acute coronary syndrome after PCI, can also improve infarct-related vascular TIMI blood Flow, significantly improve the reperfusion effect and prognosis [1]. The purpose of this study was to review the comparative analysis of domestic GP b / a receptor antagonist Hinvining on acute myocardial infarction